Correlation of monocyte/HDL ratio (MHR) with inflammatory parameters in obese patients diagnosed with polycystic ovary syndrome

Abstract

Objectives: Monocyte/high density lipprotein (HDL) ratio (MHR) has been reported to be associated with obesity and polycystic ovarian syndrome (PCOS). In this study, it was aimed to evaluate whether there is a relationship between PCOS and MHR and inflammatory parameters, to investigate the relationship level of MHR and lymphocyte/monocyte ratio (LMR), which are easily accessible inflammatory and oxidative stress markers, with obese women with PCOS, and to determine the usability of MHR as a predictive marker for PCOS. Material and methods:The study included 64 PCOS-patients who were admitted to Gynecology clinics and 52 healthy women. Results:The mean MHR (12.5 ± 4.6) in the PCOS group was significantly higher than the control group (10.4 ± 4.0) (p = 0.01). In the examination performed by combining the groups PCOS and obesity status, the mean MHR value in the PCOS-obese group was significantly higher than all the other groups (p = 0.004). In the ROC analysis, the threshold value of 10.1 for MHR was found to have a sensitivity of 84.8% and specificity of 58.5% in determining the association between PCOS and obesity (AUC: 0.721; p < 0.001; LB: 0.628; UB: 0.814; CI 95%). Accordingly, the rate of those with MHR level of 10.1 and above was significantly higher in the PCOS group compared to the control group (67.2% vs 40.4%) (p = 0.001). In the logistic regression analysis, the determination is increased by 3,026 times (odds ratio; 1.401-6.535) in predicting the presence of PCOS in those with MHR value of 10.1 and above, and 7,576 times (Odds ratio; 2.652-21.646) in predicting the presence of PCOS + obesity. was found to be. Correlation analysis in PCOS patients revealed that the MHR value was negatively correlated with age (p = 0.001; r = -0.412), LMR (p = 0.003; r = -0.377), and total cholesterol [p = 0.018; correlation coefficient (r) = -0.302]. Conclusions:This study findings showed that MHR level is significantly related to PCOS, and especially MHR values above 10.1 may be a significant predictive marker for PCOS. Our study findings also show that an association of PCOS and obesity is a very important trigger on MHR.

Analysis of serum homocysteine concentration in patients less than 35 years of age with polycystic ovary syndrome and hyperandrogenism

“…Hyperandrogenemia in patients with PCOS may cause disorders of adipocyte morphology and function, resulting in the increase of inflammatory factors, such as serum interleukin-6, tumor necrosis factor α, lymphocyte/monocyte ratio and Creactive protein; it also interferes with the insulin signaling pathway and causes a decrease in insulin sensitivity [2,3]. However, the metabolism of high density lipoprotein and low density lipoprotein in the serum of obese PCOS patients is disorder, and the status of insulin resistance is more serious [4].…”

Monocyte to High-Density lipoprotein and Apolipoprotein A1 Ratios: Novel Indicators for Metabolic Syndrome in Chinese Newly Diagnosed Type 2 Diabetes

“…MHR was also considered as indicators of oxidative stress and systemic inflammatory disease. Several studies reported that MHR showed a powerful predictive value for chronic inflammatory disease like PCOS (10), peripheral artery disease (25), central retinal artery occlusion (26), Parkinson's Disease (11), nonalcoholic fatty liver disease (27), and STelevation myocardial infarction (28). Furthermore, Jiang et al found that MHR was significantly related to all-cause and cardiovascular mortality in the general population independent of established risk factors (9).…”

“…Monocyte–to–HDL-c ratio (MHR) was also recognized as indicators of oxidative stress and systemic inflammation, which has been identified as a predictive marker for some disease, such as CVD, polycystic ovarian syndrome (PCOS), and Parkinson’s Disease ( 9 – 11 ). Besides fewer studies reported the predictive value of MHR for MetS in patients with PCOS ( 10 , 12 ), there was no study that has focused on the potential ability of MHR for MetS in newly diagnosed T2DM. Apolipoprotein A1 (ApoA1) is a constituent of HDL-c produced by liver that participates in the process of peripheral cholesterol reverse transportation to the liver, which was also considered as protective proteins in CVD ( 13 ).…”

“…High-density lipoprotein (HDL-c) is considered as "good cholesterol" that can bind lipid molecules such as triglyceride (TG) and cholesterol and participate in the cholesterol clearance, resulting in decreased CVD risk (8). Monocyte-to-HDL-c ratio (MHR) was also recognized as indicators of oxidative stress and systemic inflammation, which has been identified as a predictive marker for some disease, such as CVD, polycystic ovarian syndrome (PCOS), and Parkinson's Disease (9)(10)(11). Besides fewer studies reported the predictive value of MHR for MetS in patients with PCOS (10,12), there was no study that has focused on the potential ability of MHR for MetS in newly diagnosed T2DM.…”

Association between MHR and MAFLD: A Single-center Retrospective Study

“…Monocyte /HDL-C ratio (MHR) is a newly proposed marker representing increased in ammatory response and decreased anti-in ammatory and antioxidant capacity [11]. MHR signi cantly increases with obesity, polycystic ovary syndrome, metabolic syndrome, and diabetes [12,13]. In addition, increased MHR positively correlates with metabolic indexes, such as serum uric acid, blood glucose, and serum lipids [14,15].…”